Biogen reported Phase 2 success for litifilimab, its anti-BDCA2 antibody program in lupus, positioning the drug as a potential pillar in its immunology pipeline. In 24 weeks, the company said patients showed improvement in skin lesions, with 14.7% reaching the predefined response threshold, as outlined in its #AAD26 presentation.